Company / Capital Returned to Shareholders per Share
Regeneron Pharmaceuticals Capital Returned to Shareholders per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Returned to Shareholders per Share
$33.50
FY2025
5-year range
$2.41 / $50.80
FY2021-FY2025
Trend
+46.1%
vs FY2024
Sector context
#1 of 51
Health Care
What the data says
Among 51 Health Care companies, Regeneron Pharmaceuticals is in the top 2% for capital returned to shareholders per share. Capital Returned to Shareholders per Share has fluctuated over the past 10 years, ranging from $0.00 in FY2017 to $50.80 in FY2022.
Based on SEC 10-K filings.
33.50 in FY2025 with a 5-year CAGR of +287.5%. Ranks 1st among 51 companies in Health Care.
Improved from $19.92 to $33.50 over the past 2 years.
Health Care sector context is included.
Capital Returned to Shareholders per Share over time
Growth rates
- 3-Year CAGR
- -13.0%
- 5-Year CAGR
- +287.5%
- 10-Year CAGR
- -
Sector benchmark
+1124.7% above sector average
Key checks
Key Insights
- In FY2025, capital returned to shareholders per share increased 46.1% year-over-year.
- Ranks #1 out of 51 companies in the Health Care sector.
- Peak capital returned to shareholders per share was recorded in FY2022.
- Lowest capital returned to shareholders per share in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score 3.03 (safe zone, above 2.9 threshold)
- Strong profit margin: 32.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital Returned to Shareholders per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $33.50 | +46.1% |
| FY2024 | $22.94 | +15.1% |
| FY2023 | $19.92 | -60.8% |
| FY2022 | $50.80 | +2010.0% |
| FY2021 | $2.41 | +6181.4% |
| FY2020 | $0.04 | -98.4% |
| FY2019 | $2.38 | +6192.1% |
| FY2018 | $0.04 | - |
| FY2017 | $0.00 | - |
| FY2016 | $0.00 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026